Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1951

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

R-CHOP Vs. R-CHOP+X for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

Oren Pasvolsky, MD, Alon Rozental, MD, Pia Raanani, MD, Anat Gafter-Gvili, MD, Ronit Gurion

Blood (2019) 134 (Supplement_1): 5331.

https://doi.org/10.1182/blood-2019-126013

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma

Miguel A Canales, MD PhD, Thomas A Buchholz, MD, James R Mason, MD, Joana M Parreira, MD, Monique S Tomiczek, MSc, Kai Hübel, MD

Blood (2019) 134 (Supplement_1): 5269.

https://doi.org/10.1182/blood-2019-123638

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Cassidy Brothers, MD MSC

Blood (2019) 134 (Supplement_1): 5631.

https://doi.org/10.1182/blood-2019-125378

Published: 2019

Journal Articles

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Lacey S. Williams, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 5697.

https://doi.org/10.1182/blood-2019-122932

Published: 2019

Journal Articles

Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCG)-ALL-2015

Blood (2019) 134 (Supplement_1): 2576.

https://doi.org/10.1182/blood-2019-128523

Published: 2019

Journal Articles

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Prashant Tembhare, MD, Gaurav Narula, MD, Gaurav Chatterjee, MD, Twinkle Khanka, Mahima Sanyal, Sitaram Ghogale, Nikhil Patkar, MD, Nilesh Deshpande, Yajamanam Badrinath, Sumeet Gujral, MD, Shripad Banavali, MD, Papagudi Ganesan Subramanian, MD

Blood (2019) 134 (Supplement_1): 2585.

https://doi.org/10.1182/blood-2019-128347

Published: 2019

Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD

Blood (2019) 134 (Supplement_1): 2649.

https://doi.org/10.1182/blood-2019-129805

Published: 2019

Journal Articles

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Vania Phuoc, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Bijal Shah, MD, Lubomir Sokol, MD PhD, Julio Chavez

Blood (2019) 134 (Supplement_1): 2898.

https://doi.org/10.1182/blood-2019-122393

Published: 2019

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Journal Articles

Quantitative Analysis of Tumor-Specific BCL2 Expression in DLBCL: Refinement of Prognostic Relevance of BCL2

Jin Roh, Hyungwoo Cho, MD, Dok Hyun Yoon, Jung Yong Hong, A-Neum Lee, Hyeon-Seok Eom, Hyewon Lee, MD, Weon Seo Park, Jae Ho Han, MD, Seong Hyun Jeong, Joon Seong Park, MD, Hyo-Kyung Pak, So-Woon Kim, MD, Sang-Yeob Kim, Cheolwon Suh, Jooryung Huh, Chan-Sik Park

Blood (2019) 134 (Supplement_1): 2901.

https://doi.org/10.1182/blood-2019-130279

Published: 2019

Journal Articles

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Shin Lee, MD, Negoro Eiju, Morishita Tetsuji, MD PhD, Kei Fujita, MD, Hideaki Yamauchi, MD, Kana Oiwa, MD, Takanori Ueda, MD PhD, Takahiro Yamauchi, MD PhD

Blood (2019) 134 (Supplement_1): 2902.

https://doi.org/10.1182/blood-2019-121527

Published: 2019

Journal Articles

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

Blood (2019) 134 (Supplement_1): 2844.

https://doi.org/10.1182/blood-2019-129664

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

NARROW

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

The different flavors and splices of MCL

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

R-CHOP Vs. R-CHOP+X for Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Expanding the Indications for Ibrutinib: Complete Remission Obtained By Induction with Ibrutinib Followed By Consolidative Ahsct in Refractory Primary CNS Lymphoma

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Lack of Benefit of Extended Vincristine and Dexamethasone Pulses during Maintenance Treatment of Childhood Acute Lymphoblastic Leukemia: A Multicenter Randomized Controlled Study of Chinese Children Cancer Group (CCCG)-ALL-2015

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Quantitative Analysis of Tumor-Specific BCL2 Expression in DLBCL: Refinement of Prognostic Relevance of BCL2

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404)

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only